Vident Investment Advisory LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 32,316 shares of the biotechnology company’s stock, valued at approximately $783,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in Exelixis by 2.0% in the second quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock valued at $1,077,530,000 after purchasing an additional 857,452 shares during the period. Vanguard Group Inc. grew its holdings in Exelixis by 7.2% in the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock valued at $626,635,000 after purchasing an additional 1,706,893 shares during the period. Matrix Capital Management Company LP grew its holdings in Exelixis by 8.8% in the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after purchasing an additional 1,225,000 shares during the period. Goldman Sachs Group Inc. grew its holdings in Exelixis by 13.1% in the second quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock valued at $173,869,000 after purchasing an additional 818,782 shares during the period. Finally, Old Mutual Global Investors UK Ltd. grew its holdings in Exelixis by 3.1% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 5,196,829 shares of the biotechnology company’s stock valued at $127,997,000 after purchasing an additional 155,569 shares during the period. Hedge funds and other institutional investors own 81.19% of the company’s stock.

A number of research firms recently issued reports on EXEL. Cann restated a “hold” rating on shares of Exelixis in a report on Monday, October 16th. Leerink Swann downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $34.00 to $28.00 in a report on Friday, September 22nd. Oppenheimer restated a “hold” rating on shares of Exelixis in a report on Monday, October 16th. SunTrust Banks boosted their target price on shares of Exelixis from $32.00 to $35.00 and gave the company a “buy” rating in a report on Monday, October 16th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $26.00 target price on shares of Exelixis in a report on Tuesday, October 17th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $31.38.

Shares of Exelixis, Inc. (NASDAQ EXEL) opened at $25.95 on Friday. Exelixis, Inc. has a 52 week low of $14.22 and a 52 week high of $32.50. The stock has a market cap of $7,710.00, a P/E ratio of 52.63, a price-to-earnings-growth ratio of 1.20 and a beta of 1.89.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The company had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. During the same period in the previous year, the firm earned ($0.04) earnings per share. Exelixis’s revenue for the quarter was up 145.2% on a year-over-year basis. analysts expect that Exelixis, Inc. will post 0.49 EPS for the current fiscal year.

In other news, insider Gisela Schwab sold 100,000 shares of the company’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $23.79, for a total value of $2,379,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stelios Papadopoulos sold 10,000 shares of the company’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $25.40, for a total transaction of $254,000.00. The disclosure for this sale can be found here. Insiders sold 409,512 shares of company stock valued at $10,836,442 over the last 90 days. Insiders own 5.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/15/vident-investment-advisory-llc-buys-new-holdings-in-exelixis-inc-exel.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Stock Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related stocks with our FREE daily email newsletter.